Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
| ▸ | TDO2 | P48775 | 2/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490888 | 0.88 | MAPT (0.33) | LMNACYP1A2CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL1490941 | 0.84 | AAK1 (0.40) | SMN1; SMN2MAPTPDGFRBPDGFRAL3MBTL1 | |
| SCHEMBL3862496 | 0.84 | PTGES (0.41) | LMNACYP1A2CYP2C19SMN1; SMN2PDCD1 | |
| SCHEMBL4527410 | 0.81 | MAPK1 (0.41) | LMNACYP1A2CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL1897205 | 0.81 | MAPT (0.41) | LMNACYP2C19SMN1; SMN2MAPTGAA | |
| SCHEMBL1490236 | 0.81 | MAPT (0.46) | LMNACYP1A2CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL1490726 | 0.80 | CFTR (0.32) | — | |
| SCHEMBL3162668 | 0.80 | GSTM2 (0.38) | LMNASMN1; SMN2MAPTGAAL3MBTL1 | |
| SCHEMBL1490868 | 0.76 | P2RX7 (0.34) | LMNASMN1; SMN2MAPTPTGES | |
| SCHEMBL3168177 | 0.76 | MAPT (0.39) | LMNACYP1A2CYP2C19MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8017779-B2 | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-13 | — | — | US | disclosed |
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1851220-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1850849-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | Coley Pharmaceutical Group, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-13 | — | — | US | disclosed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091568-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005123080-A2 | NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | LMNA 4342/4885CYP1A2 179/4885CYP2C19 894/4885 |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | IFNG, IFNAR1, IRF3 | LMNA 3731/4885CYP1A2 1715/4885CYP2C19 3019/4885 |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, IFNG, IRF3 | LMNA 3850/4885CYP1A2 2810/4885CYP2C19 3704/4885 |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | LMNA 4535/4885CYP1A2 1087/4885CYP2C19 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.